Clinical trials: Infliximab, open to volunteers
Schizophrenia
Anti-Inflammatory Challenge in Schizophrenia
This study aims to illuminate the biological underpinnings of negative symptoms in schizophrenia-particularly motivational impairments-by probing the link between systemic inflammation and neural activity in reward-related brain…
- Trial name
- NCT05823532
- Testing
- Infliximab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Acute Pancreatitis
Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)
This study evaluates the effectiveness and safety of infliximab in the treatment of acute pancreatitis in adults. A third of participants will receive one single dose of infliximab via infusion, another third will receive a…
- Trial name
- RAPID-I (NCT03684278)
- Testing
- Infusion of 5 mg/kg Infliximab, Infusion of 10 mg/kg Infliximab
- Where
- 14 sites in United Kingdom
- Volunteers
- 240 people
- Sponsor
- University of Liverpool
Checkpoint Inhibitor, Pilot Study
Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study
To find out if taking a drug called infliximab (the "study drug") is safe and effective in reversing insulin dependence in CIADM.
- Conditions
- Checkpoint Inhibitor, Pilot Study, Diabetes Melletus
- Trial name
- NCT07257068
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Psoriasis, Psoriatic-arthritis
PsoBest - The German Psoriasis Registry
Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g.
- Trial name
- NCT01848028
- Where
- Germany
- Volunteers
- 3,500 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Crohn Disease
Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease
The objective of the SMART trial is to compare a combination therapy using azathioprine and subcutaneous infliximab versus ileocecal resection in patients with symptomatic small bowel Crohn's disease.
- Trial name
- SMART (NCT05584228)
- Testing
- Azathioprine + infliximab, Intestinal resection
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Nantes University Hospital
Inflammatory Bowel Disease, Crohn Disease
High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease.
- Conditions
- Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, Vitamin D Deficiency
- Trial name
- NCT04331639
- Testing
- vitamin D3
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Boston Children's Hospital
Cytokine Release Syndrome, Recurrent Multiple Myeloma
Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
This phase II trial tests how well giving infliximab works for the prevention of cytokine release syndrome (CRS) during treatment with teclistamab or talquetamab in patients with multiple myeloma that has come back after a period…
- Conditions
- Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT07657312
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Naresh Bumma
Acute Severe Ulcerative Colitis
Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）
This clinical trial aims to evaluate the comparative efficacy and safety of upadacitinib versus infliximab as second-line treatments for acute severe ulcerative colitis, addressing the following key questions: (1) Can…
- Trial name
- NCT07550673
- Testing
- upadacitinib, Infliximab
- Where
- 4 sites in China
- Volunteers
- 226 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Exclusive Enteral Nutrition, Ulcerative Colitis
Combined Application of EEN in the Induction of Remission in PUC
The role of exclusive enteral nutrition (EEN) in the induction of remission in pediatric patients with Crohn's disease had been well documented. But the role of EEN in children with Ulcerative Colitis (UC) was not clear.
- Conditions
- Exclusive Enteral Nutrition, Ulcerative Colitis, Children
- Trial name
- NCT04999241
- Testing
- exclusive enteral nutrition, regular food
- Volunteers
- 40 people
- Sponsor
- Children's Hospital of Fudan University
Psoriasis, Atopic Dermatitis
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
- Trial name
- NCT07352566
- Testing
- In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Crohn Disease, Infliximab
HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's Disease
Crohn's disease (CD) is a chronic non-specific inflammatory disease of the intestine. Infliximab (IFX) is a kind of one of the anti-tumor necrosis factor agents (anti-TNF) and is the main clinical treatment drug for Crohn's…
- Trial name
- NCT05813860
- Testing
- Azathioprine, Infliximab
- Volunteers
- 976 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Ulcerative Colitis (UC)
FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial
Ulcerative colitis (UC) is a chronic bowel disease. It causes inflammation of the rectum and sometimes the colon. This disease can also affect other parts of the body. It can be very difficult to live with on a daily basis.
- Trial name
- STARTER (NCT07576452)
- Testing
- 1: infliximab 2: filgotinib 3: ustekinumab 4: vedolizumab, 1: ustekinumab 2: vedolizumab 3: infliximab 4: filgotinib, 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab
- Where
- 13 sites in France
- Volunteers
- 240 people
- Sponsor
- University Hospital, Clermont-Ferrand
IBD (Inflammatory Bowel Disease)
MICI-BIO: Study on Patient With Chronic Inflammatory Bowel Disease
This is a monocentric, non-profit prospective cohort study with longitudinal biological sampling. The study will include patients with IBD starting biological therapy with infliximab.
- Trial name
- MICI-BIO (NCT07470502)
- Testing
- Infliximab level analysis in biological samples
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Meyer Children's Hospital IRCCS
Crohn's Disease
Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD
The goal of this prospective, multicenter, open-label, randomized controlled, non-inferiority trial is to test efficacy and safety of formulation switching between subcutaneous (SC) infliximab and intravenous (IV) infliximab in…
- Trial name
- CHAMELEON (NCT06064864)
- Testing
- Infliximab-Dyyb
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Asan Medical Center
Inflammatory Bowel Disease (IBD), Crohn Disease (CD)
PROactive and Early Infliximab Monitoring and OPTimization in Inflammatory Bowel Disease
Infliximab (IFX) is a Food and Drug administration (FDA)-appoved monoclonal antibody medication targeting tumor necrosis factor (TNF) widely used in inflammatory bowel disease (IBD) to treat intestinal inflammation and improve…
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- PROMPT-IBD (NCT06758024)
- Testing
- Infliximab
- Where
- Chile
- Volunteers
- 72 people
- Sponsor
- Pontificia Universidad Catolica de Chile
IBD - Inflammatory Bowel Disease, RA - Rheumatoid Arthritis
A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease
A subcutaneous formulation of infliximab CT-P13 (Remsima, Celltrion) has been approved for clinical use in inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) after demonstration of pharmacokinetic (PK) non-inferiority…
- Trial name
- NCT07120152
- Testing
- Subcutaneous infliximab CT-P13 Remsima®SC
- Volunteers
- 439 people, healthy volunteers welcome
- Sponsor
- Erwin Dreesen
Colitis, Ulcerative
Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis
This study aims to examine patients with acute severe UC who are refractory to intravenous corticosteroids and determine whether a strategy of using upadacitinib first followed by infliximab in upadacitinib non-responders is…
- Trial name
- RESCUE UC (NCT06660693)
- Testing
- Upadacitinib Oral Product
- Where
- Canada
- Volunteers
- 134 people
- Sponsor
- McMaster University
Ulcerative Colitis
AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative Colitis
Ulcerative Colitis (UC) is a chronic Inflammatory Bowel Disease (IBD) characterized by a multifactorial etiology, a variable involvement of large bowel, and a relapsing-remitting course.
- Trial name
- ADVANCED-UC (NCT05931458)
- Testing
- Appendectomy, Infliximab
- Volunteers
- 94 people
- Sponsor
- Federico II University
Rheumatoid Arthritis, Ankylosing Spondylitis
Korean College of Rheumatology Biologics and Targeted Therapy Registry
We established a nationwide biologics and targeted synthetic DMARDs registry (in the form of an inception cohort) to study the safety profiles in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- KOBIO (NCT01965132)
- Testing
- Biologic or targeted synthetic DMARD
- Where
- South Korea
- Volunteers
- 10,000 people
- Sponsor
- Seoul National University Hospital
IBD (Inflammatory Bowel Disease), Crohn Disease (CD)
Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease
This observational study aims to identify genes that may affect how patients with inflammatory bowel disease respond to anti-TNF treatment and why some patients lose response to treatment over time.
- Conditions
- IBD (Inflammatory Bowel Disease), Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- NCT07644117
- Testing
- This is an observational study with no intervention. Patients will receive anti- TNF therapy as part of their standard care
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Shmuel Kivity, MD